Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial

BACKGROUND: Currently, there are no randomized trials on the effect of antiangiogenic therapy in patients with esophageal squamous cell carcinoma (ESCC). The following study investigated the efficacy and safety of anlotinib in patients with advanced ESCC who were previously treated with chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jing, Xiao, Juxiang, Fang, Wentao, Lu, Ping, Fan, Qingxia, Shu, Yongqian, Feng, Jifeng, Zhang, Shu, Ba, Yi, Zhao, Yang, Liu, Ying, Bai, Chunmei, Bai, Yuxian, Tang, Yong, Song, Yan, He, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940231/
https://www.ncbi.nlm.nih.gov/pubmed/33586360
http://dx.doi.org/10.1002/cam4.3771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940231/
https://www.ncbi.nlm.nih.gov/pubmed/33586360
http://dx.doi.org/10.1002/cam4.3771

Ejemplares similares